It is characterized with a few genomic alterations in TP53 and p16 but may also exhibit phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) alterations, copy-number gains in TNF receptor-associated factor 3 and E2F transcription factor 1 (E2F1), and lack of cyclin D1 (CCND1) amplification as compared to HPV-negative cancers [9]. This evidence concerns the gene E2F1 and cancer.